Gina Columbus

Nivolumab demonstrated a significant extension in overall survival versus chemotherapy in patients with unresectable advanced or recurrent esophageal cancer that is refractory to or intolerant of fluoropyrimidine plus platinum-based therapy.

The investigational mitomycin formulation UGN-101 demonstrated a 57% complete response rate in patients with low-grade upper-tract urothelial cancer.

Josep Piulats, MD, discussed the TRITON2 data and how rucaparib could shift treatment for these biomarker-specific patients with metastatic castration-resistant prostate cancer.

Eli Lilly and Company has announced that it will acquire the biopharmaceutical company Loxo Oncology for $235 per share in cash or an estimated $8 billion.

Waun Ki Hong, MD, reflects on his career milestones in head and neck cancer and how his pioneer initiatives continue to make inroads across malignancies.

The Japan Pharmaceuticals and Medical Devices Agency has approved pembrolizumab for 5 new indications, including melanoma, advanced microsatellite instability-high tumors, and 3 expanded uses in advanced non–small cell lung cancer.

The FDA has approved dasatinib tablets in combination with chemotherapy for the treatment of pediatric patients ≥1 year of age with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.

The FDA has approved ravulizumab-cwvz as an injection treatment of adult patients with paroxysmal nocturnal hemoglobinuria, a rare blood disorder that leads to hemolysis.

Enzalutamide plus androgen deprivation therapy (ADT) significantly improved radiographic progression-free survival compared with ADT alone.

The FDA has approved tagraxofusp-erzs infusion for the treatment of adult and pediatric patients, aged ≥2 years, with blastic plasmacytoid dendritic cell neoplasm.

The FDA has approved a longer-acting version of calaspargase pegol-mknl (Asparlas) as a component of a multiagent chemotherapy regimen for pediatric and young adult patients aged 1 month to 21 years with acute lymphoblastic leukemia.

The PARP inhibitor olaparib demonstrated a statistically significant and clinically meaningful improvement in objective response rate in patients with BRCA-mutant ovarian cancer who have relapsed on at least 2 prior lines of therapy.

The FDA has granted an accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma.

The FDA has approved olaparib as a maintenance treatment for patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to frontline platinum-based chemotherapy.

Neratinib led to a statistically significant improvement in centrally confirmed progression-free survival compared with lapatinib and capecitabine in patients with HER2-positive metastatic breast cancer who have failed 2 or more prior lines of HER2-directed therapy.

The European Medicines Agency's Committee for Medicinal Products for Human Use has granted a positive opinion to dasatinib in combination with chemotherapy for the treatment of pediatric patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.

The European Medicines Agency’s Committee for Medicinal Products for Human Use recommended to expand the approval of single-agent rucaparib as a maintenance therapy in adult patients with platinum-sensitive relapsed high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy.

The FDA has approved atezolizumab for use in combination with bevacizumab, carboplatin, and paclitaxel for the first-line treatment of patients with metastatic nonsquamous non-small cell lung cancer.

The phase III TAHOE trial evaluating second-line rovalpituzumab tesirine as a treatment for patients with advanced small cell lung cancer has stopped enrollment as recommended by an Independent Data Monitoring Committee.

Accelerated partial breast irradiation following lumpectomy was marginally not found to be equivalent to whole breast irradiation to control ipsilateral breast tumor recurrence.

Adjuvant treatment with capecitabine in patients with early-stage triple-negative breast cancer did not significantly improve disease-free or overall survival compared with observation, according to results from the phase III GEICAM/CIBOMA trial that were presented at the 2018 San Antonio Breast Cancer Symposium.

The addition of brentuximab vedotin to chemotherapy led to a clinically meaningful improvement in progression-free and overall survival in patients with CD30-expressing peripheral T-cell lymphoma.

The first-line combination of ibrutinib (Imbruvica) and obinutuzumab (Gazyva) was associated with a 77% reduction in the risk for disease progression or death compared with chemoimmunotherapy in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.

Lisocabtagene maraleucel appeared tolerable and induced an 81.3% best overall response rate and 43.8% complete response rate in heavily pretreated, high-risk patients with chronic lymphocytic leukemia who previously received ibrutinib.

Two-year maintenance therapy with ixazomib led to a 39% improvement in progression-free survival compared with placebo in patients with newly diagnosed multiple myeloma who achieved a partial response to induction treatment with a proteasome inhibitor and/or an immunomodulatory agent following autologous stem cell transplant.

Concurrent treatment with ibrutinib and the CD19-targeted chimeric antigen receptor T-cell therapy JCAR014 was well tolerated and led to an overall response rate of 83% in patients with relapsed or refractory chronic lymphocytic leukemia.

The FDA has approved the first rituximab biosimilar, CT-P10, for the treatment of adult patients with CD20-positive, B-cell non-Hodgkin lymphoma as a single agent or in combination with chemotherapy.

Ahead of the 2018 ASH Annual Meeting, multiple myeloma experts Sundar Jagannath, MBBS, selected the most pivotal abstracts in their field.

The European Commission has granted approval to the biosimilar Ziextenzo, a biosimilar for pegfilgrastim, as a treatment to reduce the duration of neutropenia and incidence of febrile neutropenia that is associated with anticancer chemotherapy.

The European Commission has approved brigatinib (Alunbrig) for the treatment of adult patients with ALK-positive non–small cell lung cancer who were previously treated with crizotinib (Xalkori).